相似文献
1
Cancer immunology and immunotherapy.癌症免疫学与免疫疗法。
Cancer Biol Med. 2021 Nov 24;18(4):931-3. doi: 10.20892/j.issn.2095-3941.2021.0036.
2
The local microenvironment matters in preclinical basic and translational studies of cancer immunology and immunotherapy.在癌症免疫学和免疫治疗的临床前基础及转化研究中，局部微环境至关重要。
Cancer Cell. 2022 Jul 11;40(7):701-702. doi: 10.1016/j.ccell.2022.05.016. Epub 2022 Jun 16.
3
Translating Science into Survival: Report on the Fifth International Cancer Immunotherapy Conference.将科学转化为生存之道：第五届国际癌症免疫治疗会议报告。
Cancer Immunol Res. 2020 Jan;8(1):3-6. doi: 10.1158/2326-6066.CIR-19-0888.
4
Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?癌症免疫学与免疫治疗中的有害细胞因子：生物标志物与靶点？
Ann Oncol. 2021 Nov;32(11):1311-1313. doi: 10.1016/j.annonc.2021.09.010. Epub 2021 Sep 21.
5
What's new in surgical oncology: impact of immunology and tumour biology.外科肿瘤学的新进展：免疫学和肿瘤生物学的影响
J R Coll Surg Edinb. 1990 Dec;35(6):341-4.
6
Tumor immunology.肿瘤免疫学
Immunol Ser. 1990;50:513-33.
7
Bispecific antibodies in cancer immunotherapy.癌症免疫疗法中的双特异性抗体。
Hum Vaccin Immunother. 2016 Oct 2;12(10):2491-2500. doi: 10.1080/21645515.2016.1187802. Epub 2016 Jun 1.
8
Cancer immunotherapies targeting the PD-1 signaling pathway.靶向PD-1信号通路的癌症免疫疗法。
J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9.
9
Cancer immunotherapy comes of age.癌症免疫疗法崭露头角。
Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673.
10
Editorial: Decoding immunologic complex systems in cancer: the cutting-edge technologies revolutionizing cancer immunology and immunotherapy.社论：解读癌症中的免疫复杂系统：彻底改变癌症免疫学和免疫治疗的前沿技术
Front Immunol. 2023 May 4;14:1208589. doi: 10.3389/fimmu.2023.1208589. eCollection 2023.
引用本文的文献
1
The Role of the TIMP1/LINC01615 Axis as a Regulator of the EMT Pathway in Gastric Cancer.TIMP1/LINC01615轴在胃癌上皮-间质转化途径中作为调节因子的作用
Biol Proced Online. 2025 Aug 18;27(1):31. doi: 10.1186/s12575-025-00297-y.
2
Comprehensive analysis reveals CLDN9 is a new biomarker in human cancers and immunotherapeutic target for glioblastoma multiforme.综合分析表明，CLDN9是人类癌症中的一种新生物标志物，也是多形性胶质母细胞瘤的免疫治疗靶点。
Cancer Cell Int. 2025 Jun 18;25(1):216. doi: 10.1186/s12935-025-03852-5.
3
Preclinical advance in nanoliposome-mediated photothermal therapy in liver cancer.纳米脂质体介导的肝癌光热治疗的临床前进展
Lipids Health Dis. 2025 Jan 31;24(1):31. doi: 10.1186/s12944-024-02429-x.
4
The safety and anti-tumor effect of multiple peptides-pulsed dendritic cells combined with induced specific cytotoxic T lymphocytes for patients with solid tumors.多种肽段致敏树突状细胞联合诱导特异性细胞毒性 T 淋巴细胞治疗实体瘤患者的安全性和抗肿瘤作用。
Front Immunol. 2023 Oct 24;14:1284334. doi: 10.3389/fimmu.2023.1284334. eCollection 2023.
5
Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors.重新利用药物治疗实体瘤：关注免疫检查点抑制剂。
Cancer Biol Med. 2023 Nov 6;20(11):856-68. doi: 10.20892/j.issn.2095-3941.2023.0281.
6
First-line tremelimumab plus durvalumab and chemotherapy chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States.一线 tremelimumab 联合度伐利尤单抗与单纯化疗治疗转移性非小细胞肺癌：美国的一项成本效益分析。
Front Pharmacol. 2023 Jul 20;14:1163381. doi: 10.3389/fphar.2023.1163381. eCollection 2023.
7
Identification of Genes Associated with Prognosis and Immunotherapy Prediction in Triple-Negative Breast Cancer via M1/M2 Macrophage Ratio.通过 M1/M2 巨噬细胞比值鉴定与三阴性乳腺癌预后和免疫治疗预测相关的基因。
Medicina (Kaunas). 2023 Jul 11;59(7):1285. doi: 10.3390/medicina59071285.
8
FN1 mediated activation of aspartate metabolism promotes the progression of triple-negative and luminal a breast cancer.FN1 介导的天冬氨酸代谢激活促进三阴性和腔 A 型乳腺癌的进展。
Breast Cancer Res Treat. 2023 Oct;201(3):515-533. doi: 10.1007/s10549-023-07032-9. Epub 2023 Jul 17.
9
Nano Ultrasound Contrast Agent for Synergistic Chemo-photothermal Therapy and Enhanced Immunotherapy Against Liver Cancer and Metastasis.纳米超声造影剂用于协同化疗-光热治疗和增强免疫治疗肝癌及其转移。
Adv Sci (Weinh). 2023 Jul;10(21):e2300878. doi: 10.1002/advs.202300878. Epub 2023 May 10.
10
Eliciting pyroptosis to fuel cancer immunotherapy: mechanisms and strategies.引发细胞焦亡以推动癌症免疫治疗：机制与策略
Cancer Biol Med. 2022 Jul 21;19(7):948-64. doi: 10.20892/j.issn.2095-3941.2022.0049.
本文引用的文献
1
Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357.自体细胞因子诱导杀伤细胞免疫疗法联合化疗治疗鳞状非小细胞肺癌的随机、多中心、开放标签试验：NCT01631357
Signal Transduct Target Ther. 2020 Oct 19;5(1):244. doi: 10.1038/s41392-020-00337-x.
2
A guide to cancer immunotherapy: from T cell basic science to clinical practice.癌症免疫疗法指南：从 T 细胞基础科学到临床实践。
Nat Rev Immunol. 2020 Nov;20(11):651-668. doi: 10.1038/s41577-020-0306-5. Epub 2020 May 20.
3
B cells and tertiary lymphoid structures promote immunotherapy response.B 细胞和三级淋巴结构促进免疫治疗反应。
Nature. 2020 Jan;577(7791):549-555. doi: 10.1038/s41586-019-1922-8. Epub 2020 Jan 15.
4
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.免疫相关不良反应和免疫检查点抑制剂的抗肿瘤疗效。
J Immunother Cancer. 2019 Nov 15;7(1):306. doi: 10.1186/s40425-019-0805-8.
Zotero 插件